The cytosolic chaperonin T-complex protein (TCP) 1-ring complex (TRiC) has been shown to exert neuroprotective effects on axonal transport through clearance of mutant Huntingtin (mHTT) in Huntington's disease. However, it is presently unknown if TRiC also has any effect on axonal transport in wild-type neurons. Here, we examined how TRiC impacted the retrograde axonal transport of brain-derived neurotrophic factor (BDNF). We found that expression of a single TRiC subunit significantly enhanced axonal transport of BDNF, leading to an increase in instantaneous velocity with a concomitant decrease in pauses for retrograde BDNF transport.
| INTRODUCTION
The cytosolic chaperonin T-complex protein (TCP) 1-ring complex (TRiC) or chaperonin containing TCP-1(CCT) binds to approximately 10% of the eukaryotic newly translated polypeptides and promotes their folding.
1,2 CCT also binds to misfolded proteins and regulates their oligomerization/aggregation. 1, 3, 4 Recent studies suggest that CCT exerts strong neuroprotective effects in Huntington's disease (HD). [5] [6] [7] [8] [9] Expression of either a single or all eight subunits (CCT1- protein, leading to improved cellular or neuronal functions. [5] [6] [7] [8] 10 In addition, CCT inhibited amyloid fiber assembly of α-synuclein mutant A53T, associated with Parkinson disease (PD), pointing out a similar neuroprotective role for CCT in PD. 11 Furthermore, CCT has been implicated to play a role in Alzheimer's disease (AD) susceptibility. 12 Importantly, we previously found that either CCT3 or CCT5 expression could normalize the deficit in axonal transport in neurons from the BACHD mouse model of HD. 8 However, it is unclear if the CCT subunit has any role in the axonal transport in wild-type neurons.
Tau is a microtubule-associated protein that regulates microtubule dynamics and stability. [13] [14] [15] [16] [17] [18] [19] [20] Tau thus plays an important role in facilitating axonal transport that is critical for neuronal survival and maintenance. Aberrant function in tau is associated with a class of Abbreviations: AD, Alzheimer's disease; BDNF, brain-derived neurotrophic factor; CCT, chaperonin containing TCP-1; CDK5, cyclin-dependent kinase 5; CHO cells, Chinese hamster ovary cells; DIV, days in vitro; FTDP-17, frontotemporal dementia with parkinsonism linked to chromosome 17; GSK3β, glycogen synthase kinase 3 beta; HD, Huntington's disease; HEK293T cells, human embryonic kidney 293T cells; Hsp, heat shock proteins; mHTT, mutant Huntingtin; NFT, neurofibrillary tangles; PD, Parkinson's disease; QD-BDNF, quantum dot-labeled brain-derived neurotrophic factor; shRNA, short hairpin RNA; TCP, T-complex protein; TRiC, chaperonin T-complex protein (TCP) 1-ring complex neurodegenerative diseases called tauopathies. These diseases are characterized by tau hyperphosphorylation and/or expression of mutant tau protein, leading to aggregation of tau and formation of tau-containing deposits in the brain. [21] [22] [23] The best-known tauopathy is AD, whose pathological hallmarks include both β-amyloid peptidecontaining amyloid plaques and tau-containing neurofibrillary tangles (NFTs). 24 In addition, missense mutations in tau have been identified in patients with frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17) tauopathy. 21, 25 Studies have shown that molecular chaperones such as heat shock proteins (Hsps) are involved in tau-related neurodegenerative diseases through recognizing abnormal tau and reducing its level by facilitating tau dephosphorylation or degradation. [26] [27] [28] [29] [30] For instance, Hsp90 was shown to maintain the stability of mutant tau P301L,28 , one of the most prevalent FTDP-17 tau mutations. 31, 32 Given the potential role of CCT chaperonin on axonal transport in HD, we investigated here whether CCT could modulate axonal transport in wild-type neurons. We found that expression of a single CCT subunit CCT5, improved axonal transport function as measured by an increase in instantaneous velocity with a concomitant decrease in pauses for retrograde transport of BDNF. Mechanistically, CCT5 acted through the cyclin-dependent kinase 5 (CDK5) pathway to increase the level of ptau which resulted in detachment of tau from microtubules. Our study provides evidence that upregulation of TRiC/CCT subunit increases tau phosphorylation that impacts retrograde axonal transport.
2 | RESULTS
| CCT modulates axonal transport of BDNF via a tau-dependent mechanism
Our previous study has shown that either CCT3 or CCT5 delivery rescued the deficit in axonal BDNF transport in cultured cortical neurons from the BACHD mouse model of HD. 8 To test if CCT had any effect on axonal transport in wild-type neurons, we used lentivirus to express an Avi-tagged human CCT5 construct in rat E18 cortical neurons. To mark transduced neurons, GFP was also expressed in the same vector but under a promoter different from hCCT5-Avi. Four days post transduction, lenti-mediated expression routinely achieved an infection efficiency of~95% as revealed by the GFP signal ( Figure 1A ).
Neurons were transduced with either CCT5-lenti or control-lenti at days in vitro (DIV)5 ( Figure 1B ). At DIV9, we used a well-established system to measure retrograde axonal transport of quantum dotlabeled BDNF (QD-BDNF) by live cell imaging. We next investigated whether CCT5-induced enhancement of axonal transport function was tau-dependent, as tau plays an important role in modulating axonal transport under both physiological and pathological conditions. 22 To establish a role of tau in CCT5-mediated enhancement of axonal transport of BDNF, we elect to examine E18 cortical neurons from tau −/− mouse ( Figure 2 ). The experimental design was shown in Figure 2A . 
| CCT regulates the level of CDK5/p35/p25
Tau binds to microtubule to impact axonal cargo transport. [13] [14] [15] [16] [17] [18] [19] [20] Previous studies have shown that tau overexpression compromised vesicle transport in a phosphorylation-dependent manner in Drosophila.
36
Therefore, we predicted that CCT subunit may affect axonal cargo transport through mediating tau phosphorylation. We first evaluated the level and activity of glycogen synthase kinase 3 beta (GSK3β) and cyclin-dependent kinase 5 (CDK5), two prominent kinases that play important roles in tau phosphorylation in AD. 37 CDK5 could be activated by neuron-specific activator p35 as well as its truncated form p25. 38 Interestingly, CCT5 overexpression significantly increased the level of CDK5, p35 and p25 ( Figure 3A-D) . This effect appeared to be dependent on the level of CCT5 because overexpression of CCT5 did not change the endogenous level of CCT subunits such as CCT2, CCT4 and CCT5 in rat primary E18 cortical neurons ( Figure S1A ). We also observed that CCT5 upregulation increased Hsp70 level ( Figure S1A ).
To further define the role of CCT complex in CDK5/p35, we used a lenti-short hairpin RNA (shRNA) specific for rat CCT2 (rCCT2-shRNAlenti) to reduce the level of CCT complex in rat primary E18 cortical neurons. Knocking down CCT2 has been shown to effectively reduce the levels of all eight CCT subunits. 39 Both control lenti and rCCT2-shRNA-lenti also expressed GFP. The rCCT2-shRNA-lenti resulted in a~40% reduction in the level of CCT2, 4, 5 ( Figure S1B 
| CCT subunit modulates tau phosphorylation
To validate the effect of CCT on tau phosphorylation, we analyzed the AT8 site of ptau, as AT8 is one of the best well-known pathological epitopes. 40 Expression of hCCT5-Avi induced a significant increase in AT8, but had no effect on the total tau level ( Figure 4A ). In addition, The distribution of stationary vs nonstationary of QD-BDNF puncta in each condition is presented in H, *P < 0.05, **P < 0.01, and ***P < 0.001, unpaired Student's t test ( Figure 4G ). Based on these findings, we conclude that GSK3β may not contribute importantly to CCT5-induced increase in AT8 in our studies.
We thus conclude that CCT5 expression selectively modulated the activity of CDK5, but not GSK3β.
We showed that ApiCCT1 did not show any impact on the level of AT8
( Figure S4C ). We also tested the mobility retardation profile of tau and CCT5 using native gel electrophoresis. We found overexpressed CCT5 formed a complex with a molecular weight (MW) between 720 and 1048 kD, from which tau was absent ( Figure S4D ). It has been reported that tau phosphorylation promotes formation of tau oligomer. 41 Our results showed that CCT5, although increased ptau, had no effect on tau WT oligomerization ( Figure S4D) ; as a control, tau P301L has been shown to form various oligomers in native gel 42 ( Figure S4D ).
| CCT modulates binding of tau to microtubules
Phosphorylated tau has reduced capacity to bind to microtubules. 43, 44 We then assessed the effect of CCT5 expression on tau binding to microtubules by measuring free tau and microtubulebound tau in primary rat cortical neurons. Expression of CCT5 induced a decrease in the level of tau bound to the Taxol-stabilized microtubules as detected in the pellet fraction (P) ( Figure 5A ). The ratio of tau in the pellet to the supernatant fractions (P/S) was markedly decreased in CCT5-overexpressed neurons, as compared with that in controls ( Figure 5A ). In addition, roscovitine treatment normalized the distribution of tau induced by CCT5 ( Figure 5A ).
These results provide evidence that CCT5 acts through CDK5 to promote tau phosphorylation to induce detachment of tau from microtubules.
One of the most striking subcellular phenotypes of tau overexpression is the formation of microtubule bundling, likely due to hyperstabilization of microtubules by excessive tau. 45 We reversed by a tau phosphor-mimic mutant. 46 We further examined if polymerization of microtubules was impacted by CCT5 expression. We found that CCT5 had no effect on microtubule polymerization in primary neurons ( Figure 5C ). In addition, expression of CCT5 did not affect tubulin acetylation (a marker for stable microtubules) in primary cortical neurons ( Figure 5D ). These results indicate that CCT-mediated tau phosphorylation weakens tau binding to microtubules and reduces tau-mediated microtubule bundling without affecting the stability of microtubules.
Hypophosphorylated tau, not pseudophosphorylated tau, was found to impair axonal transport likely due to enhanced binding of tau to microtubule in Drosophila. ing sensory neuropathy with spastic paraplegia in patients 47 and a C450Y mutation in CCT4 was found to be associated with an early onset sensory neuropathy in Sprague-Dawley rat strain. 48 Conversely, increasing TRiC/CCT has been shown to be neuroprotective. Expression of all eight or a single CCT subunit inhibits aggregation of mHTT and prevents its cellular toxicity. [5] [6] [7] [8] 10 Enhanced expression of CCT subunits or exogenously added ApiCCT1-mediated clearance of In primary embryonic-cultured neurons, we found the antibodies (PHF, AT8 and tau) all detected a major band with a MW of~50 kD and a second band with a slightly higher MW of~54 kD. Tau has six spliced isoforms: 0N3R, 1N3R, 2N3R, 0N4R, 1N4R, 2N4R. 49, 50 While expression of the 4R forms (0N4R, 1N4R, 2N4R) is only detected starting at 2 months of age in mice, 51 the 0N3R form of tau is the predominant form expressed in neurons at embryonic stages. 51 Low level of 1N3R form is also detected. 51 Therefore, the 50 and 54 kD bands that we observed in our studies likely represents the 0N3R, 1N3R
form of tau, respectively. 51 The two forms of tau, 0N3R and 1N3R, differ only in the presence of an N-terminal insert (29 residues) in 1N3R, but with exact same microtubule binding domains in the C-terminus. Our results showed that phosphorylated forms of both 0N3R
and 1N3R were present in rat E18 cortical neurons because LiCl treatment decreased the intensity of both bands. Of note, the difference in the relative intensity of the 54 kD band varied among different sets of experiments in our study. We believe that this is likely due to slight variations in the experimental conditions such as exposure times.
Nevertheless, results from samples within the same set of experiments (ie, Figure 3A left panel or right panel) were consistent. Furthermore, transfected CCT5 subunits formed a complex in which tau was apparently absent. Therefore, the effect of CCT5 on Tau plays an important role in axonal transport of vesicles, organelles as well as other cargoes, 22 as evident by acute reduction of hippocampal tau in adult mice resulting learning and memory deficits. 63 However, overexpression of tau, as observed early in some forms of tauopathies, 64 also impaired axonal transport before the breakdown of microtubules. 13, 14, 36, 46, 65 Interestingly, this inhibitory effect of excessive tau could be rescued by phosphorylation of tau. 65 On the other hand, hyperphosphorylation drives tau to detach from microtubules, thus destabilizing microtubules that could also interrupt axonal transport. 22, 66 Furthermore, detached soluble and hyperphosphorylated tau tends to aggregate into paired helical filaments, 67 which causes spatial clogging within axon. 66 Therefore, cellular tau, presented either in excess amount or in hyperphosphorylated forms,
shows deleterious effect on axonal function.
Mechanistically, tau has been shown to compete with motor proteins for binding to microtubule 13 and reduce the number of engaged motors per cargo for transport. 68 As a cargo itself, tau also probably competes with other cargoes for availability of motor. 69 Further tau was reported to regulate the release of cargo from kinesin involving PP1/GSK3β. 70 Therefore, excessive non-phosphorylated tau may pose an adverse effect on axonal transport, as revealed in a recent study in Drosophila, in which hypophosphorylated tau, was found to impair axonal transport, likely due to enhanced binding of tau to microtubule. 36 The function of tau could be complemented by other microtubule-associated protein like MAP1b, 71 because no obvious alternation of axonal transport in neurons that were either partially or completely depleted of tau. 72, 73 It is conceivable that reduction in tau binding to microtubules by overexpression of CCT subunit makes track more favorable for motor proteins and cargoes to move along microtubules. Indeed, reintroducing tau WT but not tau P301L , into tau −/− primary neurons rescued the effect of CCT on axonal transport of BDNF. Our results are consistent with that tau P301L exhibited a weaker binding capacity to microtubules than tau .
Consistent with previous studies, [77] [78] [79] we have demonstrated that CCT acted on CDK5 to modulate retrograde axonal transport. It is possible that CDK5 signals through a mechanism involving dynein regulators Ndel1/Lis1 to stimulate retrograde axonal transport. 77 Interestingly, CDK5 phosphorylation of Ndel1 was reported to inhibit processive mobility of dynein-driven cargoes. 78 The effect of CCT5 on retrograde axonal transport of QD-BDNF may arise from both direct tau-dependent mechanism(s) and indirect mechanism(s) including CDK5-mediated Ndel1 phosphorylation.
Although there are reports that the GSK3/ptau connection also affects axonal transport, 20, 80 our results show that GSK3β is unlikely involved in CCT-induced phosphorylation of tau. Evidence supporting this notion includes that: (1) CCT5 expression had no effect on the level and activity of GSK3β as revealed by phosphorylation-specific antibodies (both pSer9 and pTyr216); (2) LiCl pretreatment of cortical neurons did not prevent CCT5-mediated increase in AT8, albeit the measure reduced basal level of AT8 signal; and (3) inhibition of CDK5 effectively abolished CCT5-induced tau phosphorylation in AT8. Nevertheless, TRiC/CCT complex modulates~10% of the eukaryotic proteins, we cannot exclude the possibility that other effectors of GSK3β, in addition to CDK5/p35, might be affected and synergistically enhance the CCT5-mediated effect on axonal transport.
It has been well established that tau regulates the activity of various protein kinases. 70 Similarly, TRiC/CCT also regulates various many important kinases such as sphingosine kinase 1, 81 mitogen-activated protein kinases 82 and phosphoinositide 3-kinase. 83 CCT could potentially regulate the activity of these kinases through transcriptional alterations or turnover at the protein level or both. In this study, we have demonstrated that CCT acted on CDK5/p35 to impact tau phosphorylation and function. This is a novel finding in defining cellular Recent studies have demonstrated that mRNA levels of the TRiC/ CCT complex were decreased in brain samples of AD patients. 84 Further CCT5 expression was found to be also decreased in Alzheimer's disease. 85 It is thus important to understand how decreased activity of CCT complex or individual CCT subunit impacts the stabilization and turnover of tau, whose pathogenic species also accumulates in AD. Although the physiological implications remain to be defined, our study has established that increased expression of CCT5 had a clear impact on tau-mediated functions such as axonal transport.
| MATERIALS AND METHODS

| Ethic statement
This study was performed strictly according to the recommendations 
| Plasmids
The following plasmids were obtained from the Addgene: 
| Live imaging of axonal transport of quantum dot-labeled brain-derived neurotrophic factor
Monobiotinylated BDNF conjugated to Quantum dot 655 (Inviotrgen) (QD-BDNF) was prepared and used for tracking axonal retrograde transport of BDNF in microfluidic chamber-cultured neurons by live imaging. 34 Following 2-hour starvation in neurobasal media, QD-BDNF (final concentration of 0.1 nM) was added to the distal chamber and allowed to incubate for another 4 hours before imaging. All images were captured with a Leica DMI6000B inverted microscope using a ×100 oil objective lens with a Rolera XR CCD camera (Q Imaging) in an environmental chamber (37 C, 5% CO 2 ). Kymographs generation and analysis of puncta movement were carried out with ImageJ software.
| Immunocytochemistry
Established protocols were followed for immunocytochemistry. 87 Transfected CHO cells were fixed in 4% paraformaldehyde for 15 minutes at room temperature and incubated with a mouse anti-α-tubulin antibody (DM1A, Invitrogen) overnight at 4 C followed by secondary antibody conjugated with Alexa Fluor 647 (Invitrogen) for 1 hour at room temperature. Primary cortical neurons were also fixed as above after virus infection for 4 to 5 days and incubated with antitau (Genscript) antibody. They were then mounted and scanned with a Leica TCS SPE confocal microscope.
| Drug treatment
Primary embryonic cortical neurons were incubated with 20 μM roscovitine (Santa Cruz Biotechnology) for 4 to 8 hours or 20 mM LiCl (Enzo Life Sciences) for 2 hours prior to cell lysis for immunoblotting.
HEK293T cells expressing various constructs alone or in combination (EGFP-tau WT , EGFP-tau P301L , mCherry, CCT5-mCherry) were treated with either 20 μM roscovitine, or 20 mM LiCl for 2 hours before assays.
| Native PAGE assay
Transfection of HEK293T cells was performed with EGFP-tau WT and mCherry or CCT5-mCherry or EGFP-tau P301L for 48 hours. The cells were harvested in lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 0.5% Triton X-100 supplemented with protease inhibitor mixture as above) on ice. Native electrophoresis was performed at neutral pH 7.5 using the NativePAGE Novex 4%-16% Bis-Tris Gel system (Life Technologies).
| Microtubule-binding assay of tau
Microtubule-binding assay was performed as described previously. 
| Western blotting
Cell lysates were boiled in SDS-PAGE loading buffer for 5 minutes. 87, 89 The samples were separated on 4% to 10% SDS-PAGE gel, trans- 
| Statistical analyses
All data are presented as the mean AE SEM. Statistical analyses were performed using PRISM (GraphPad Software Inc.) with the two-tailed and paired or unpaired Student's t test or one-way ANOVA. The significance levels were as follows: *P < 0.05, **P < 0.01 and ***P < 0.001.
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